Vaccines For Type 1 Diabetes: Prevention or Reversal?


Journal

Current diabetes reviews
ISSN: 1875-6417
Titre abrégé: Curr Diabetes Rev
Pays: United Arab Emirates
ID NLM: 101253260

Informations de publication

Date de publication:
2021
Historique:
received: 23 12 2019
revised: 12 02 2020
accepted: 21 02 2020
pubmed: 1 4 2020
medline: 8 1 2021
entrez: 1 4 2020
Statut: ppublish

Résumé

Type 1 diabetes mellitus (T1DM) is an autoimmune disease which leads to the destruction of pancreatic β-cells, thereby causing insufficient insulin production. Globally, around 98, 200 children and adolescents below 15 years of age and almost 128,900 subjects below 20 years of age develop T1DM annually, along with severe complications deteriorating their quality of life. In India alone, around 15,900 incident cases below 15 years have reported annually. Hence, its prevention and reversal are significant. Unlike other chronic diseases, T1DM involves the presence of various autoantigens, which can be targeted by proper immunisation. The development of reliable immuno-regulatory surrogate markers would be of great benefit. Vaccines can be one of such strategies in the journey to prevent T1DM. It would not only benefit greatly to reduce the sufferings caused due to diabetic complications but could also help to reverse T1DM, by modulating the autoantigenic immunological reactions and prevent further degradation of pancreatic β-cells. This review collates a wide range of information related to the vaccine studies conducted in animal and human models to prevent and reverse T1DM.

Identifiants

pubmed: 32223735
pii: CDR-EPUB-105529
doi: 10.2174/1573399816666200330145501
doi:

Substances chimiques

Insulin 0
Vaccines 0

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

30-36

Informations de copyright

Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.

Auteurs

Shivani Desai (S)

Department of Pharmacology, Dr. D.Y. Patil Institute of Pharmaceutical Sciences and Research, Pune, India.

Shubhangi Buchade (S)

Department of Pharmacology, Dr. D.Y. Patil Institute of Pharmaceutical Sciences and Research, Pune, India.

Sohan Chitlange (S)

Dr. D.Y. Patil Institute of Pharmaceutical Sciences and Research, Pune, India.

Hitt Sharma (H)

Serum Institute of India, Pune, India.

Dhiraj Bhombe (D)

Department of Pharmacology, Dr. D.Y. Patil Institute of Pharmaceutical Sciences and Research, Pune, India.

Sunil Shewale (S)

Serum Institute of India, Pune, India.

Pramod Pujari (P)

Serum Institute of India, Pune, India.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH